* Corvus Pharmaceuticals Inc CRVS.OQ reported a quarterly
adjusted loss of 12 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -17 cents. The mean expectation of
four analysts for the quarter was for a loss of 13 cents per
share. Wall Street expected results to range from -15 cents
to -12 cents per share.
* Reported revenue was zero; analysts expected zero.
* Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 12 cents.
* The company reported a quarterly loss of $5.7 million.
* Corvus Pharmaceuticals Inc shares had risen by 7.9% this
quarter and gained 9.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 26.6%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is $7.50
This summary was machine generated from LSEG data May 6 at 09:24
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.13 -0.12 Beat
Dec. 31 2023 -0.12 -0.14 Missed
Sep. 30 2023 -0.12 -0.12 Met
Jun. 30 2023 -0.14 -0.14 Met